Princeton, New Jersey, USA, November 16, 2026
Palatin Technologies, Inc. has presented new preclinical findings from its next-generation melanocortin-4 receptor (MC4R)-selective peptide agonist programmes at ObesityWeek® 2026, highlighting potential advances in the development of treatments for rare neuroendocrine obesity disorders. The findings demonstrate potent MC4R activity, substantial selectivity over the melanocortin-1 receptor (MC1R), and reductions in body weight and food intake in preclinical animal models. The company is investigating these compounds to address limitations associated with existing MC4R-targeted therapies, particularly MC1R-related hyperpigmentation and the need for more convenient dosing schedules. Palatin also reported that its proprietary peptide lipidation technology extended drug exposure in preclinical studies, supporting the potential for once-weekly or less frequent administration. The company selected PL2001, a long-acting lipidated MC4R-selective peptide agonist, as its clinical development candidate. IND-enabling and chemistry, manufacturing, and controls activities are progressing, with first-in-human studies targeted for the first half of 2027. The findings were presented at the international obesity research meeting taking place in Washington, D.C., from November 14 to 17, 2026.
Selective MC4R Activity May Address Hyperpigmentation
Palatin’s research focuses on activating MC4R, a receptor involved in regulating appetite, energy balance, and body weight. Impaired signalling through the melanocortin pathway can contribute to severe hunger and early-onset or difficult-to-manage obesity in certain rare conditions. The company’s research programmes include novel cyclic peptides in the PL1000 series and long-acting lipidated peptides in the PL2000 series. According to the preclinical data presented at ObesityWeek, these compounds demonstrated potent MC4R activity with minimal to no functional activity at MC1R in laboratory assays. The reported selectivity ranged from more than 100-fold to more than 200-fold for MC4R over MC1R. This distinction is important because activation of MC1R is associated with hyperpigmentation, a recognised adverse effect of currently approved MC4R agonist therapies. By designing compounds with greater receptor selectivity, Palatin aims to reduce or potentially eliminate this limitation. However, these findings are based on in-vitro testing and have not yet established that the candidates will prevent hyperpigmentation in humans. Further studies will be needed to evaluate their safety, tolerability, and clinical performance.
Preclinical Weight-Loss Findings and Extended Drug Exposure
The company reported that both selective cyclic peptides and long-acting lipidated peptides produced significant reductions in body weight and food intake in diet-induced obese mouse models. The PL1002 candidate demonstrated dose-dependent reductions following twice-daily administration, while a single subcutaneous dose of PL2001 also produced dose-dependent effects. These results provide early evidence supporting the pharmacological activity of the compounds, although animal-model findings cannot establish clinical effectiveness in people with obesity. Palatin also highlighted its proprietary peptide lipidation technology, which is intended to extend drug exposure while maintaining receptor potency and selectivity. In preclinical pharmacokinetic studies, lipidated peptides showed an approximately 24-hour half-life in rodents and more than 168 hours in dogs, compared with approximately two hours for non-lipidated selective peptides. The company believes these results support the possibility of once-weekly or less frequent subcutaneous administration. If confirmed in clinical development, a longer dosing interval could offer a more convenient treatment approach than daily injections. The company also reported preliminary cardiovascular observations: PL1001 showed no observed effects on heart rate or blood pressure at the efficacious doses and time points evaluated in preclinical studies. Additional cardiovascular safety investigations are planned to further assess the compounds.
PL2001 Moves Toward First-in-Human Studies
Among the programmes presented, PL2001 has been selected as Palatin’s lead clinical development candidate. The company is progressing IND-enabling studies and chemistry, manufacturing, and controls activities, with first-in-human testing targeted for the first half of 2027 and initial clinical data anticipated in the second half of that year. Alongside its injectable peptide candidates, Palatin is continuing research into orally administered MC4R-selective peptides and complementary oral small-molecule agonists. Its development strategy is focused on potential treatments for hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome, which are rare conditions associated with disturbances in appetite regulation and the melanocortin pathway. The research was presented in a poster titled “In Vitro and Preclinical Characterization of Novel Selective Melanocortin-4 Receptor Agonists” by Luipa Khandker, Ph.D., at ObesityWeek 2026. While the results provide encouraging early-stage evidence for receptor selectivity, weight-related activity, and extended drug exposure, the candidates remain investigational. Clinical trials will be required to determine whether these findings translate into safe and effective treatments for patients.
Source: Palatin Technologies press release



